Literature DB >> 15219971

Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets?

Peter M Fischer1, David P Lane.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15219971     DOI： 10.1016/j.tips.2004.04.011

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


× No keyword cloud information.
  22 in total

1.  Protein-protein interactions for cancer therapy.

Authors:  Curtis C Harris
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-01       Impact factor: 11.205

Review 2.  Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc.

Authors:  Mu-Shui Dai; Yetao Jin; Jayme R Gallegos; Hua Lu
Journal:  Neoplasia       Date:  2006-08       Impact factor: 5.715

3.  Beta-peptides with improved affinity for hDM2 and hDMX.

Authors:  Elizabeth A Harker; Douglas S Daniels; Danielle A Guarracino; Alanna Schepartz
Journal:  Bioorg Med Chem       Date:  2009-01-23       Impact factor: 3.641

Review 4.  Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.

Authors:  Damir Bojadzic; Peter Buchwald
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

5.  Regulation of the MDM2-p53 pathway by ribosomal protein L11 involves a post-ubiquitination mechanism.

Authors:  Mu-Shui Dai; Dingding Shi; Yetao Jin; Xiao-Xin Sun; Yanping Zhang; Steven R Grossman; Hua Lu
Journal:  J Biol Chem       Date:  2006-06-27       Impact factor: 5.157

Review 6.  Oncogenic protein interfaces: small molecules, big challenges.

Authors:  Tracy L Nero; Craig J Morton; Jessica K Holien; Jerome Wielens; Michael W Parker
Journal:  Nat Rev Cancer       Date:  2014-03-13       Impact factor: 60.716

7.  MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy.

Authors:  Kensuke Kojima; Marina Konopleva; Ismael J Samudio; Masato Shikami; Maria Cabreira-Hansen; Teresa McQueen; Vivian Ruvolo; Twee Tsao; Zhihong Zeng; Lyubomir T Vassilev; Michael Andreeff
Journal:  Blood       Date:  2005-07-12       Impact factor: 22.113

8.  Catalytic, Enantioselective Synthesis of Stilbene cis-Diamines: A Concise Preparation of (-)-Nutlin-3, a Potent p53/MDM2 Inhibitor.

Authors:  Tyler A Davis; Jeffrey N Johnston
Journal:  Chem Sci       Date:  2011-03-25       Impact factor: 9.825

9.  Enhanced antitumor activity of combinations of free and HPMA copolymer-bound drugs.

Authors:  J Hongrapipat; P Kopecková; S Prakongpan; J Kopecek
Journal:  Int J Pharm       Date:  2007-09-22       Impact factor: 5.875

10.  Peptide, Peptidomimetic, and Small-molecule Antagonists of the p53-HDM2 Protein-Protein Interaction.

Authors:  Peter M Fischer
Journal:  Int J Pept Res Ther       Date:  2006-03-15       Impact factor: 1.931
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.